Total Payments
$4.3M
2024 Payments
$518,605
Companies
48
Transactions
5,048
Medicare Patients
7,977
Medicare Billing
$3.3M
Payment Breakdown by Category
Other$3.4M (77.8%)
Travel$543,000 (12.5%)
Consulting$337,267 (7.8%)
Food & Beverage$84,563 (1.9%)
Education$627.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.8M | 879 | 63.9% |
| Honoraria | $604,696 | 241 | 13.9% |
| Travel and Lodging | $543,000 | 1,679 | 12.5% |
| Consulting Fee | $337,267 | 114 | 7.8% |
| Food and Beverage | $84,563 | 2,130 | 1.9% |
| Education | $627.19 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $1.1M | 1,025 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $664,373 | 683 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $568,423 | 842 | $0 (2024) |
| US WorldMeds, LLC | $432,773 | 582 | $0 (2020) |
| Amneal Pharmaceuticals LLC | $354,731 | 315 | $0 (2024) |
| Kyowa Kirin, Inc. | $299,171 | 281 | $0 (2024) |
| MDD US Operations, LLC | $277,290 | 281 | $0 (2024) |
| Adamas Pharmaceuticals, Inc. | $221,377 | 181 | $0 (2021) |
| ABBVIE INC. | $105,796 | 139 | $0 (2024) |
| Lundbeck LLC | $97,067 | 141 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $518,605 | 596 | Teva Pharmaceuticals USA, Inc. ($163,613) |
| 2023 | $647,968 | 727 | Teva Pharmaceuticals USA, Inc. ($179,707) |
| 2022 | $643,959 | 697 | Teva Pharmaceuticals USA, Inc. ($153,858) |
| 2021 | $556,981 | 570 | Teva Pharmaceuticals USA, Inc. ($121,197) |
| 2020 | $424,900 | 540 | Teva Pharmaceuticals USA, Inc. ($115,837) |
| 2019 | $730,842 | 771 | Teva Pharmaceuticals USA, Inc. ($170,073) |
| 2018 | $534,541 | 726 | Teva Pharmaceuticals USA, Inc. ($147,863) |
| 2017 | $291,475 | 421 | ACADIA Pharmaceuticals Inc ($130,407) |
All Payment Transactions
5,048 individual payment records from CMS Open Payments — Page 1 of 202
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $4,053.00 | General |
| Category: NEUROLOGY | ||||||
| 12/27/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $187.60 | General |
| Category: NEUROLOGY | ||||||
| 12/27/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $180.90 | General |
| Category: NEUROLOGY | ||||||
| 12/27/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $74.96 | General |
| Category: NEUROLOGY | ||||||
| 12/26/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $4,053.00 | General |
| Category: NEUROLOGY | ||||||
| 12/24/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $5.30 | General |
| Category: Neuromodulation | ||||||
| 12/20/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | Cash or cash equivalent | $296.70 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/20/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | Cash or cash equivalent | $113.90 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/20/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | Cash or cash equivalent | $73.97 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/20/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: Musculoskeletal | ||||||
| 12/20/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/18/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: Central Nervous System | ||||||
| 12/16/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/13/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/12/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $332.84 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.76 | General |
| Category: Neuropsychiatry | ||||||
| 12/11/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Travel and Lodging | In-kind items and services | $786.90 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/11/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $12.85 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/11/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $7.14 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 12/11/2024 | MDD US Operations, LLC | Apokyn (Drug) | Food and Beverage | In-kind items and services | $6.97 | General |
| Category: APOMORPHINE HYDROCHLORIDE | ||||||
| 12/10/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Honoraria | Cash or cash equivalent | $2,026.50 | General |
| Category: NEUROLOGY | ||||||
| 12/09/2024 | Merz Pharmaceuticals, LLC | INBRIJA (Drug) | Food and Beverage | In-kind items and services | $10.56 | General |
| Category: Parkinson's Disease | ||||||
| 12/05/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/04/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 1,873 | 115,011 | $2.0M | $809,700 |
| 2022 | 17 | 2,102 | 116,118 | $2.1M | $841,845 |
| 2021 | 16 | 2,022 | 106,834 | $2.1M | $861,735 |
| 2020 | 20 | 1,980 | 87,998 | $1.9M | $768,848 |
Total Patients
7,977
Total Services
425,961
Medicare Billing
$3.3M
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 102 | 53,206 | $532,060 | $257,661 | 48.4% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 105 | 46,899 | $468,990 | $186,883 | 39.8% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2023 | 67 | 12,074 | $217,332 | $118,885 | 54.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 818 | 1,229 | $226,136 | $107,800 | 47.7% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 153 | 408 | $213,300 | $53,402 | 25.0% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2023 | 158 | 368 | $101,936 | $23,788 | 23.3% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 61 | 176 | $92,928 | $18,642 | 20.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 85 | 85 | $28,135 | $11,355 | 40.4% |
| 64643 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | Office | 2023 | 42 | 122 | $27,206 | $8,429 | 31.0% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Office | 2023 | 77 | 143 | $41,327 | $8,209 | 19.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 76 | $9,804 | $5,057 | 51.6% |
| 64646 | Injection of chemical for paralysis of nerve muscles on trunk, 1-5 muscles | Office | 2023 | 33 | 63 | $18,963 | $2,884 | 15.2% |
| 64644 | Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | Office | 2023 | 12 | 29 | $9,773 | $2,769 | 28.3% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 52 | 63 | $9,639 | $2,150 | 22.3% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 19 | 48 | $7,152 | $1,506 | 21.1% |
| 95970 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | Office | 2023 | 20 | 22 | $2,156 | $280.58 | 13.0% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 106 | 52,031 | $520,310 | $253,495 | 48.7% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2022 | 99 | 46,126 | $461,260 | $183,072 | 39.7% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2022 | 83 | 14,934 | $268,812 | $143,779 | 53.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 740 | 1,054 | $193,936 | $86,158 | 44.4% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 166 | 439 | $227,880 | $57,009 | 25.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 199 | 199 | $65,869 | $31,117 | 47.2% |
| 64642 | Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | Office | 2022 | 159 | 311 | $86,147 | $21,958 | 25.5% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2022 | 56 | 158 | $83,424 | $17,436 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 103 | 188 | $24,252 | $12,427 | 51.2% |
About Dr. Cherian Karunapuzha, MD
Dr. Cherian Karunapuzha, MD is a Neurology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2007. The National Provider Identifier (NPI) number assigned to this provider is 1881896397.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Cherian Karunapuzha, MD has received a total of $4.3M in payments from pharmaceutical and medical device companies, with $518,605 received in 2024. These payments were reported across 5,048 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.8M).
As a Medicare-enrolled provider, Karunapuzha has provided services to 7,977 Medicare beneficiaries, totaling 425,961 services with total Medicare billing of $3.3M. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Oklahoma City, OK
- Active Since 06/05/2007
- Last Updated 11/10/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1881896397
Products in Payments
- AUSTEDO (Drug) $869,881
- INGREZZA (Drug) $662,177
- NUPLAZID (Drug) $568,423
- GOCOVRI (Drug) $337,571
- RYTARY (Drug) $328,090
- Austedo XR (Drug) $248,048
- APOKYN (Drug) $211,205
- MYOBLOC (Biological) $202,971
- NOURIANZ (Drug) $181,488
- BOTOX (Biological) $132,067
- Nourianz (Drug) $117,684
- Xadago (Drug) $115,463
- NORTHERA (Drug) $97,049
- INBRIJA (Drug) $89,494
- CREXONT (Drug) $28,369
- Gocovri (Drug) $25,366
- Xeomin (Biological) $15,175
- Apokyn (Drug) $12,787
- XEOMIN (Biological) $11,607
- ONGENTYS (Drug) $8,214
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Oklahoma City
Gabriel Pardo, M.d, M.D
Neurology — Payments: $1.6M
Neurology $1.6M
Marguerite Butchee, Md, MD
Neurology — Payments: $254,555
Neurology $254,555
Chelsea Berkley, Md, MD
Neurology — Payments: $228,923
Neurology $228,923
Aaron Farrow, Md, MD
Neurology — Payments: $195,234
Neurology $195,234
Ashish Masih, M.d, M.D
Neurology — Payments: $153,184
Neurology $153,184
Christi Pendergraft, Md, MD
Neurology — Payments: $95,478
Neurology $95,478